{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7"},{"groupId":"OG001","value":"28.0"}]}],"title":"None (7 days post-dose) [N= 110, 107]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2"},{"groupId":"OG001","value":"41.1"}]}],"title":"Mild (7 days post-dose) [N= 110, 107]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4"},{"groupId":"OG001","value":"16.8"}]}],"title":"Moderate (7 days post-dose) [N= 110, 107]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"12.1"}]}],"title":"Severe (7 days post-dose) [N= 110, 107]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.9"}]}],"title":"Extreme (7 days post-dose) [N= 110, 107]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"46.2"}]}],"title":"None (24 weeks post-dose) [N= 85, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8"},{"groupId":"OG001","value":"37.2"}]}],"title":"Mild (24 weeks post-dose) [N= 85, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9"},{"groupId":"OG001","value":"15.4"}]}],"title":"Moderate (24 weeks post-dose) [N= 85, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"},{"groupId":"OG001","value":"1.3"}]}],"title":"Severe (24 weeks post-dose) [N= 85, 78]"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Extreme (24 weeks post-dose) [N= 85, 78]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"description":"Participant scored their current pain intensity in the most affected joint of the gout flare on a 5-point Likert Scale (none, mild, moderate, severe, extreme). It participant had a new flare, they also scored the maximum amount of acute gout pain in the most affected joint since the onset of a new flare on 5 point Likert scale (none, mild, moderate, severe, extreme).","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set includes all patients that received study drug. 'N' in each category indicates participants with observations analyzed for this endpoint at specified time points.","reportingStatus":"POSTED","timeFrame":"7 days post dose (randomization), 24 weeks post-dose","title":"Patient's Assessment of Gout Pain Intensity in the Most Affected Joint (Likert Scale)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}